Literature DB >> 32887990

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.

Joseph E Tota1, Frank Struyf2, Allan Hildesheim1, Paula Gonzalez3, Martin Ryser4, Rolando Herrero3,5, John Schussler6, Naveen Karkada4, Ana Cecilia Rodriguez7, Nicolas Folschweiller4, Carolina Porras7, Mark Schiffman1, John T Schiller8, Wim Quint9, Aimée R Kreimer1, Matti Lehtinen10, Cosette M Wheeler11, Joshua N Sampson1.   

Abstract

Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  HPV; clearance; efficacy; progression; vaccination

Mesh：

Substances：

Year:  2021        PMID： 32887990      PMCID： PMC8248553          DOI： 10.1093/infdis/jiaa561

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Authors:  Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M Garland; Xavier Castellsagué; S Rachel Skinner; Dan Apter; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Henry Kitchener; Júlio C Teixeira; James Hedrick; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; Newton S De Carvalho; Maria Julieta V Germar; Klaus Peters; Adrian Mindel; Philippe De Sutter; F Xavier Bosch; Marie-Pierre David; Dominique Descamps; Frank Struyf; Gary Dubin
Journal:  Lancet Oncol       Date:  2011-11-08       Impact factor: 41.316

2.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Authors:  Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen
Journal:  Lancet Oncol       Date:  2011-11-08       Impact factor: 41.316

3.  A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.

Authors:  A G Bais; I Beckmann; J Lindemans; P C Ewing; C J L M Meijer; P J F Snijders; T J M Helmerhorst
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

4.  Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.

Authors:  Joseph E Tota; Frank Struyf; Joshua N Sampson; Paula Gonzalez; Martin Ryser; Rolando Herrero; John Schussler; Naveen Karkada; Ana Cecilia Rodriguez; Nicolas Folschweiller; Carolina Porras; Mark Schiffman; John T Schiller; Wim Quint; Aimée R Kreimer; Cosette M Wheeler; Allan Hildesheim
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

5.  AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

Authors:  Arnaud M Didierlaurent; Sandra Morel; Laurence Lockman; Sandra L Giannini; Michel Bisteau; Harald Carlsen; Anders Kielland; Olivier Vosters; Nathalie Vanderheyde; Francesca Schiavetti; Daniel Larocque; Marcelle Van Mechelen; Nathalie Garçon
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

6.  Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.

Authors:  Francis J Dessy; Sandra L Giannini; Catherine A Bougelet; Troy J Kemp; Marie-Pierre M David; Sylviane M Poncelet; Ligia A Pinto; Martine A Wettendorff
Journal:  Hum Vaccin       Date:  2008-11-11

7.  Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.

Authors:  Rolando Herrero; Sholom Wacholder; Ana C Rodríguez; Diane Solomon; Paula González; Aimee R Kreimer; Carolina Porras; John Schussler; Silvia Jiménez; Mark E Sherman; Wim Quint; John T Schiller; Douglas R Lowy; Mark Schiffman; Allan Hildesheim
Journal:  Cancer Discov       Date:  2011-09-09       Impact factor: 39.397

8.  Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Authors:  Allan Hildesheim; Paula Gonzalez; Aimee R Kreimer; Sholom Wacholder; John Schussler; Ana C Rodriguez; Carolina Porras; Mark Schiffman; Mary Sidawy; John T Schiller; Douglas R Lowy; Rolando Herrero
Journal:  Am J Obstet Gynecol       Date:  2016-02-16       Impact factor: 8.661

9.  Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Authors:  Tim Palmer; Lynn Wallace; Kevin G Pollock; Kate Cuschieri; Chris Robertson; Kim Kavanagh; Margaret Cruickshank
Journal:  BMJ       Date:  2019-04-03

10.  Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Authors:  Xavier Castellsagué; Kevin A Ault; F Xavier Bosch; Darron Brown; Jack Cuzick; Daron G Ferris; Elmar A Joura; Suzanne M Garland; Anna R Giuliano; Mauricio Hernandez-Avila; Warner Huh; Ole-Erik Iversen; Susanne K Kjaer; Joaquin Luna; Joseph Monsonego; Nubia Muñoz; Evan Myers; Jorma Paavonen; Punnee Pitisuttihum; Marc Steben; Cosette M Wheeler; Gonzalo Perez; Alfred Saah; Alain Luxembourg; Heather L Sings; Christine Velicer
Journal:  Papillomavirus Res       Date:  2016-03-14
View more
  1 in total

Review 1.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.